Stockscreener 앱 받기
39.30
0.23%
-0.09
전일 마감가:
$39.39
열려 있는:
$39.39
하루 거래량:
1.09M
Relative Volume:
0.29
시가총액:
$16.77B
수익:
$2.31B
순이익/손실:
$1.66B
주가수익비율:
17.11
EPS:
2.297
순현금흐름:
$827.02M
1주 성능:
+2.58%
1개월 성능:
-1.13%
6개월 성능:
+8.74%
1년 성능:
+55.77%
1일 변동 폭
$39.24
$39.50
1주일 범위
$38.20
$39.50
52주 변동 폭
$25.16
$41.24
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
RPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
39.25 | 16.83B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.60 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.41 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-30 | 개시 | Goldman | Buy |
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Swedbank AB Acquires 42,800 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) EVP Sells $767,600.00 in Stock - MarketBeat
Royalty Pharma Announces Planned Legal Leadership Transition - TipRanks
Royalty Pharma names McGivern as chief legal officer - StreetInsider
The Technical Signals Behind (RPRX) That Institutions Follow - news.stocktradersdaily.com
Royalty Pharma Gains from MYQORZO FDA Approval - TradingView — Track All Markets
Royalty Pharma (NASDAQ:RPRX) EVP Sells $3,060,375.22 in Stock - MarketBeat
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells 30,654 Shares of Stock - MarketBeat
Royalty Pharma : Q4 2025 Pre-Quarterly Results Communication - marketscreener.com
How risky is Royalty Pharma plc (RPD) stock compared to peersPortfolio Update Summary & AI Powered Buy and Sell Recommendations - ulpravda.ru
Royalty Pharma PLC $RPRX Shares Sold by Thrivent Financial for Lutherans - MarketBeat
Dividend Watch: How Royalty Pharma plc stock compares to growth peers - Улправда
Insider Selling: Royalty Pharma (NASDAQ:RPRX) CFO Sells 69,582 Shares of Stock - MarketBeat
Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares - MarketBeat
Royalty Pharma Insider Sold Shares Worth $766,420, According to a Recent SEC Filing - marketscreener.com
VP Urist Sells 20,000 ($766.4K) Of Royalty Pharma PLC [RPRX] - TradingView — Track All Markets
[Form 4] Royalty Pharma plc Insider Trading Activity - Stock Titan
UBS reiterates Buy rating on Nuvalent stock, citing Royalty Pharma deal - Investing.com Nigeria
Royalty Pharma buys royalty interest in Nuvalent cancer drugs for up to $315 mln - MSN
Royalty Pharma PLC (NASDAQ:RPRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Shareholder Sandy Lamm LLC Files To Sell 160,000 Of Royalty Pharma PLC [RPRX] - TradingView — Track All Markets
How Investors Are Reacting To Royalty Pharma (RPRX) Expanding Oncology Royalties With Nuvalent Deal - Sahm
Royalty Pharma shares edge higher on acquisition of oncology drug royalties - MSN
Nuvalent’s Royalty Interest Acquired by Royalty Pharma - TipRanks
Nuvalent (NASDAQ: NUVL) notes Royalty Pharma deal, 1.5% royalty on two drugs - Stock Titan
Royalty Pharma stock rises after acquiring cancer drug royalties By Investing.com - Investing.com Nigeria
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million - citybiz
Royalty Pharma stock rises after acquiring cancer drug royalties - Investing.com
Royalty Pharma Acquires Royalty Interest in Nuvalent's Potential Lung Cancer Therapies - marketscreener.com
Royalty Pharma acquires royalty interest in cancer drugs for $315 million By Investing.com - Investing.com India
Royalty Pharma acquires royalty interest in cancer drugs for $315 million - Investing.com
Royalty Pharma acquires royalty interest in Nuvalent's neladalkib and zidesamtinib for up to $315 million - marketscreener.com
Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million - Quiver Quantitative
Royalty Pharma acquires drug royalty rights for up to $315 million - StreetInsider
Royalty Pharma (RPRX): Revisiting Valuation After Fresh Analyst Upgrades and Strengthening Buy-Side Consensus - Sahm
Squarepoint Ops LLC Makes New $9.85 Million Investment in Royalty Pharma PLC $RPRX - MarketBeat
Eventide Asset Management LLC Buys 41,830 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Adage Capital Partners GP L.L.C. Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Main Street Financial Solutions LLC Buys 31,844 Shares of Royalty Pharma PLC $RPRX - MarketBeat
TD Cowen Maintains Royalty Pharma (RPRX) Buy Recommendation - Nasdaq
TD Cowen raises Royalty Pharma stock price target on growth outlook By Investing.com - Investing.com South Africa
Precision Trading with Royalty Pharma Plc (RPRX) Risk Zones - news.stocktradersdaily.com
TD Cowen Forecasts Strong Price Appreciation for Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
RPRX: TD Cowen Raises Price Target for Royalty Pharma | RPRX Sto - GuruFocus
TD Cowen raises Royalty Pharma stock price target on growth outlook - Investing.com Nigeria
Royalty Pharma (RPRX) PT Raised at TD Cowen; 'Best Ideas 2026: Unique Business' - StreetInsider
First Trust Advisors LP Has $39.78 Million Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
California Public Employees Retirement System Sells 268,263 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) EVP Sells $913,526.10 in Stock - MarketBeat
Royalty Pharma EVP Sells Over $1.6 Million in Shares - TradingView — Track All Markets
Hsbc Holdings PLC Sells 77,498 Shares of Royalty Pharma PLC $RPRX - MarketBeat
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
로열티 파마 주식 (RPRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lloyd George W. | EVP, Investments & CLO |
Dec 17 '25 |
Sale |
38.57 |
79,346 |
3,060,280 |
30,654 |
| Lloyd George W. | EVP, Investments & CLO |
Dec 18 '25 |
Sale |
38.50 |
30,654 |
1,180,053 |
0 |
| Urist Marshall | EVP, Research & Investments |
Dec 16 '25 |
Sale |
38.32 |
20,000 |
766,420 |
140,000 |
| Coyne Terrance P. | EVP & CFO |
Dec 15 '25 |
Sale |
38.36 |
69,582 |
2,669,172 |
43,510 |
0.47%
1.82%
자본화:
|
볼륨(24시간):